Short answer
ACCURAY INC (ARAY) filed its Q4 2025 10-Q quarterly report on Feb 17, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $102M (down 17.4% year over year) with net income of −$14M.
Q4 2025 key financials · XBRL
- Revenue
- $102M
- −17.4% YoY · +8.8% QoQ
- Net income
- −$14M
- −168.0% YoY · +36.5% QoQ
- Operating margin
- -11.3%
- Gross margin
- 24.0%
- EPS (diluted)
- −$0.12
- −170.6% YoY · +33.3% QoQ
Source: XBRL data from the ACCURAY INC (ARAY) Q4 2025 10-Q on SEC EDGAR. USD.
ACCURAY INC Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Ongoing inflation and supply chain challenges driving higher material and logistics costs through fiscal 2026, pressuring gross margins and net income
- Materially updated financial risk: Indebtedness $154.5M with $18M 2026 Notes due June 2026, including new warrants issued in June and Dec 2025 impacting dilution and liquidity
- Regulatory risk: Need for new FDA 510(k) clearances or international approvals on product modifications, with risks of marketing restrictions if not obtained
- Operational risk: Customer financing delays and installation postponements due to macroeconomic uncertainties have caused order cancellations impacting near-term revenue
- Market risk: Competition and rapid tech changes may render CyberKnife and TomoTherapy obsolete if unable to innovate or keep pace with market demands
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACCURAY INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.